The association between dysregulated adipocytokines in early pregnancy and development of gestational diabetes

Abell, Sally K.; Shorakae, Soulmaz; Harrison, Cheryce L.; Hiam, Danielle; Moreno-Asso, Alba; Stepto, Nigel K.; Courten, Barbora de; Teede, Helena

doi:10.1002/dmrr.2926

Cited by 38 publications

(43 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two prior studies have reported significantly higher IL-6 concentrations at 11–15 GWs among women who subsequently developed GDM. 36 37 However, in other small studies with less than 30 GDM cases the higher IL-6 concentrations among GDM cases were not statistically significant. 38–40 Our data provide the first report of longitudinal profiles of IL-6 throughout pregnancy by GDM status among a larger racially/ethnically diverse sample.…”

Section: Discussionmentioning

confidence: 79%

Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort

Francis

Hinkle

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

IntroductionSeveral adipokines are implicated in the pathophysiology of gestational diabetes mellitus (GDM), however, longitudinal data in early pregnancy on many adipokines are lacking. We prospectively investigated the association of a panel of adipokines in early and mid-pregnancy with GDM risk.Research design and methodsWithin the National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies-Singletons cohort (n=2802), a panel of 10 adipokines (plasma fatty acid binding protein-4 (FABP4), chemerin, interleukin-6 (IL-6), leptin, soluble leptin receptor (sOB-R), adiponectin, omentin-1, vaspin, and retinol binding protein-4) were measured at gestational weeks (GWs) 10–14, 15–26, 23–31, and 33–39 among 107 GDM cases (ascertained on average at GW 27) and 214 non-GDM controls. Conditional logistic regression was used to estimate ORs of each adipokine and GDM, controlling for known GDM risk factors including pre-pregnancy body mass index.ResultsThroughout pregnancy changes in chemerin, sOB-R, adiponectin, and high-molecular-weight adiponectin (HMW-adiponectin) concentrations from 10–14 to 15–26 GWs were significantly different among GDM cases compared with non-GDM controls. In early and mid-pregnancy, FABP4, chemerin, IL-6 and leptin were positively associated with increased GDM risk. For instance, at 10–14 GWs, the OR comparing the highest versus lowest quartile (ORQ4–Q1) of FABP4 was 3.79 (95% CI 1.63 to 8.85). In contrast, in both early and mid-pregnancy adiponectin (eg, ORQ4–Q1 0.14 (0.05, 0.34) during 10–14 GWs) and sOB-R (ORQ4–Q1 0.23 (0.11, 0.50) during 10–14 GWs) were inversely related to GDM risk. At 10–14 GWs a model that included conventional GDM risk factors and FABP4, chemerin, sOB-R, and HMW-adiponectin improved the estimated prediction (area under the curve) from 0.71 (95% CI 0.66 to 0.77) to 0.77 (95% CI 0.72 to 0.82).ConclusionsA panel of understudied adipokines including FABP4, chemerin, and sOB-R may be implicated in the pathogenesis of GDM with significant associations detected approximately 10–18 weeks before typical GDM screening.

show abstract

Section: Discussionmentioning

confidence: 79%

Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort

Francis

Hinkle

et al. 2020

BMJ Open Diab Res Care

View full text Add to dashboard Cite

show abstract

“…The present review also included studies that did not show a correlation between the serum levels of IL-6 and GDM, such as the study conducted by Abell et al [ 24 ], which aimed at evaluating the relationship between GDM risk using fasting glucose and serum biomarkers at the early pregnancy, and indicated that the serum IL-6 levels did not improve the ability to predict the risk of GDM. The results of another study conducted by Gümüş et al [ 29 ] aimed to evaluate the possible association between clinical and biochemical parameters with GDM and gingivitis; this study showed that there was no association between the serum IL-6 levels and GDM.…”

Section: Discussionmentioning

confidence: 99%

Role of interleukin-6 (IL-6) in predicting gestational diabetes mellitus

2020

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is the most common pregnancy-associated metabolic disorder that is steadily increasing worldwide. Early diagnosis of pregnant women susceptible to GDM is the first step for deploying effective preventive treatment to reduce maternal, fetal, and neonatal complications. The diagnostic process of GDM is still controversial and interleukin-6 (IL-6) is one of the most recent markers used for the diagnosis of GDM. In this study, we aimed to systematically review the role of IL-6 in the diagnosis of GDM. In this systematic review, Google Scholar, Scopus, PubMed, ISI Web of Science, ProQuest, and MEDLINE databases were searched using the following keywords: GDM, screening, and IL-6, with the time interval 2009–2020. The quality of articles was assessed using the Strengthening the Reporting of Observational Studies in Epidemiology checklist. Twenty-four articles with desired quality that met the inclusion criteria were selected and reviewed further. Sixteen studies showed a statistically significant association, while 8 studies did not report any relationship between IL-6 levels and GDM. Based on the results of these studies, assessing the serum IL-6 levels can be investigated a newly established diagnostic biomarker for GDM. Therefore, through early diagnosis of susceptible women, effective measures can be implemented to reduce its complications.

show abstract

“…However, no difference was indicated in obese women with GDM and normal glucose tolerance [71]. It was shown that omentin-1 concentrations lower than 38 ng/ml are associated with a 4-fold greater risk of developing GDM [67]. In a prospective study of pregnant women during the second and third trimesters, no significant differences in omentin-1 levels in the plasma of healthy women and those with GDM were identified.…”

Section: Factors Affecting Insulin Resistance In Pregnancymentioning

confidence: 99%

“…Its concentrations are lower in people with insulin resistance, i.e. those suffering from obesity, type 2 diabetes, PCOS, and GDM [67][68][69]. The highest adipokine concentrations in pregnant women were observed during the first trimester and they decreased during the second trimester [70].…”

Section: Factors Affecting Insulin Resistance In Pregnancymentioning

confidence: 99%

Insulin resistance and adaptation of pancreatic beta cells during pregnancy

Zielinska–Maciulewska

Krętowski

Szelachowska

2018

Clinical Diabetology

View full text Add to dashboard Cite

Insulin resistance is described as reduced sensitivity of the body tissues to insulin. In pregnant women insulin resistance increases during each trimester of pregnancy due to the hormones produced by the placenta and many other factors which are not yet fully recognised. Growing insulin resistance leads to an increase in beta cell mass and number and insulin secretion, which helps to maintain glucose homeostasis and normal foetal development. However, in cases of severe insulin resistance, insufficient compensation of pancreatic beta cells or reduced pancreatic beta-cell function, glycaemic levels are increased and gestational diabetes mellitus develops. The aim of the present review is to analyse the factors affecting insulin resistance and the adaptation of pancreatic beta cells during pregnancy and methods of insulin resistance assessment.

show abstract

The association between dysregulated adipocytokines in early pregnancy and development of gestational diabetes

Cited by 38 publications

References 35 publications

Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort

Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort

Role of interleukin-6 (IL-6) in predicting gestational diabetes mellitus

Insulin resistance and adaptation of pancreatic beta cells during pregnancy

Contact Info

Product

Resources

About